INTRODUCTION
The PTEN ('phosphatase and tensin homologue on chromosome 10') tumour suppressor gene on chromosome 10q23 is a dual specificity phosphatase with multiple and as yet incompletely understood roles in cellular regulation. Germline mutations in PTEN cause a spectrum of clinical syndromes, including Cowden syndrome (CS), BannayaneRileyeRuvalcaba syndrome (BRRS), and autism spectrum disorders with macrocephaly.
CS is a multisystem disorder involving increased risks for malignancy and hamartomatous tissue overgrowth. Diagnostic criteria for CS were initially established in 1996 1 and subsequent modifications have been proposed, including the addition of endometrial cancer 2 and renal cell carcinoma 3 and moving adult LhermitteeDuclos disease (LDD) into the pathognomonic category. 4 PTEN mutations were first reported in individuals with CS in 1997. 5 6 It was subsequently suggested that approximately 80% (30 of 37) of individuals with a clinical diagnosis of CS have a detectable germline coding sequence mutation in PTEN. 7 However, variable mutation detection rates have been found in other studies, including three of 27 (11%), 8 nine of 19 (47%), 5 and eight of 13 (61%) patients. 9 A small but as yet undefined proportion of CS patients have deletions or large rearrangements of the PTEN gene. A recent report found such changes in three of 15 patients who were negative for mutations using denaturing gel gradient electrophoresis (DGGE). 10 Another study found no deletions, but approximately 10% of DGGE mutation negative patients had variants in the PTEN promoter. 11 BRRS is a congenital disorder whose hallmark features are macrocephaly, hamartomatous intestinal polyps, lipomas, and pigmented macules on the penis. Additional features include developmental delay, large birth weight, and joint hyperextensibility. 12 Consensus diagnostic criteria have not been established but diagnosis is based upon presence of the hallmark features. Initially thought to be a separate disorder, BRRS was subsequently shown to be allelic to CS with approximately 60% of patients with BRRS having detectable coding sequence mutations in PTEN. 13 Most previous reports on the prevalence of the malignant and non-malignant features of CS/BRRS have been based upon data compiled from individual case reports and studies of small cohorts. More importantly, the majority of these reports were published before the adoption of the Consortium diagnostic criteria for CS in 1996. Thus, the true frequencies of the clinical features in CS and BRRS are not clearly known (see Pilarski 14 for review). The commonly reported frequencies for CS are shown in Box 1.
In an effort to obtain better data on these features and their correlation with PTEN mutations, we report here our experience with 172 patients with PTEN mutations, the largest single cohort with clinical testing reported to date. In addition, we have assessed which clinical features are most predictive of a mutation, and have developed a mutationprediction model which should be useful in clinical practice.
METHODS
Study subjects consisted of patients whose samples were sent for clinical PTEN testing to the Molecular Pathology Laboratory at The Ohio State University between 1 October 2000 and 31 October 2008. Samples were sent from clinical centres throughout the USA based on the clinical judgement of the referring provider; testing criteria were not set by our laboratory. Approximately 90% of referrals came from genetics and cancer genetics programmes, but they were accepted from all medical specialities. The study was approved by the Institutional Review Board of The Ohio State University.
Samples on 1132 subjects were submitted for analysis during the study period. Of these, 302 subjects (27 with mutations and 275 without) were not included because of incomplete clinical information provided by the ordering healthcare provider. Another 23 subjects were found to have genetic variants of uncertain significance (G44D, C71Y, T78T, A126T, 141P,  E157G, R173H, T202I, L345R, IVS1-9C/G, IVS1+7A/G, IVS3  -7delCTTTT, IVS5-11 to 20insT , and IVS6+5G/C) and were also excluded, based on benign or discrepant predictions from the Polyphen (http://genetics.bwh.harvard.edu/pph/) and/or SIFT (http://sift.jcvi.org/www/SIFT_BLink_submit.html) prediction models. Although the number of patients with an uncertain variant was small, there were no apparent differences in their clinical features compared to the whole cohort. Five subjects were excluded because of unknown gender. Thus, a total of 802 subjects (535 female; 67%) were included, 172 with germline PTEN mutations and 630 without. Sixty-seven mutations were detected through full gene sequencing, 75 through confirmation of a mutation previously identified through research testing of a proband, and 30 through testing for a mutation that had been previously identified in an affected relative.
Peripheral blood samples were obtained from all patients. For patients undergoing full gene analysis, mutation analysis of the entire coding sequence, exoneintron boundaries, and flanking sequences of the PTEN gene was performed using DNA sequencing. Primer sequences and PCR conditions have been previously described. 16 17 The clinical history on each subject was obtained through use of a 'clinical features checklist' (table 1) which ascertained for the presence or absence of each of the component features of CS/BRRS at the time of testing. Cancer diagnoses were specifically ascertained for brain, breast, endometrial, gastrointestinal (GI), renal, skin, and thyroid cancers. Simple tabulation counts were performed for all clinical features. The categories of benign breast, GI, and thyroid diseases referred specifically to structural lesions (eg, cysts, fibroids, nodules, polyps) in these systems, rather than functional disorders (eg, hypo/hyperthyroidism, coeliac disease).
All subjects were classified as to whether they met the revised International Cowden Consortium Diagnostic criteria (box 2), BRRS criteria (defined as having any three of these features: macrocephaly, lipomas, developmental delay/mental retardation or penile freckling in males), CS/BRRS overlap (meeting diagnostic criteria for both disorders) or none.
Statistical analyses
The comparison of age by gender was done using a two sample t test. We developed predictive models for mutation detection using logistic regression methods on the following subsets of subjects: males with macrocephaly, overall and by age group (#18 years and >18 years); and females, overall and by age group (#18 years and >18 years). We chose to do gender and age subgroup analyses because we felt, based on clinical experience, that the characteristics found in these groups (both gender and childhood vs adult onset of disease) were different enough to warrant separate models. Because all males age 18 and under (and the majority of males over 18) with a mutation had macrocephaly, this was not a usable variable in the modelling. Given the high clinical significance of macrocephaly, however, we restricted the modelling in males to only those with macrocephaly rather than drop the variable entirely. Therefore these 
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Renal cell cancer GU developmental anomalies models are generalisable to males who present with macrocephaly only. Stepwise modelling methods were then used to develop the most parsimonious model for each of these subgroups.
We also compared the observed cancer incidence in this cohort to that expected, based on lifetime invasive cancer risk from birth to the age of PTEN mutation detection using the National Cancer Institute's DevCan software, 18 which is based on the sex and age conditional probability of developing cancer. 19 20 Because there were too few cancers within specific sites and types of cancer to examine each site/type, we compared the observed to expected number of cases for the combined group of the three cancers for which this group should be at greater risk (breast, thyroid, and endometrial cancers).
RESULTS Genotypes
Of the 802 usable subjects, germline PTEN mutations were found in 172 (21.4%). Of these, 90 were female and 82 were male. One hundred and three different mutations were identified including two small deletions, 30 frameshift, 39 missense, 20 nonsense, and 11 splice-site mutations. Table 2 lists the distinct mutations identified in this cohort. The vast majority of mutations were seen in only one to three families each.
Of the 39 missense mutations identified, 17 (A34D, N48K, H61R, Y68H, P95L, P96R, A120E, G129E, R130G, R130L, R130Q, C136R, C136Y, Y155H, S170R, Y176C, and F347L) have been previously reported to be deleterious.
15 21e27 Seven other missense changes (C124W, G129V, G132V, I135K, G165R, S170I, and L345P) involved the same codons but different amino acid substitutions from other previously identified mutations, 15 22 23 and three are in codons adjacent to previously reported mutations (D22G near D24Y, and I32N and G36R next to A34D and M35T). 15 22 None of these changes has been reported in the National Center for Biotechnology Information's dbSNP database of genetic polymorphisms (http://www.ncbi.nlm.nih.gov/ snp, accessed November 2010). Table 3 lists the frequencies of the various clinical features for the mutation positive cohort as a whole, and broken down by gender and age. The mean age at the time of PTEN mutation diagnosis was 29.8 years for the cohort as a whole, with a significant difference between the genders (females: 34.4 years, males: 24.7 years; p¼0.002). This is likely because macrocephaly, developmental delay, and penile freckling are common in males and are easily recognised at young ages, leading to testing at an earlier age. This may also explain the finding that although males accounted for only 33% of subjects who were tested they made up almost 48% of those with a mutation.
Clinical features
The presence of mental retardation or developmental delay (MR/DD) was not ascertained until midway through the time period of this study. Of 110 subjects with mutations for whom the information was ascertained, MR/DD was reported in 10% of females and 26% of males overall, but in 18% of females and 46% of males who tested positive under age 18.
Six of the nine patients in this study who were diagnosed with LDD had a mutation. The negative patients were 1, 6, and 12 years old at the time of testing (with the 1-year-old child meeting CS diagnostic criteria), while those with mutations ranged in age from 19e64 years old. This is consistent with a prior report suggesting that adult onset LDD, but not childhood onset, is strongly linked with PTEN mutations. 28 
Phenotypes
Two hundred and thirty of the 802 subjects met CS diagnostic criteria. Of these, 79 were found to have a PTEN mutation, for a detection rate of 34%. Of subjects meeting BRRS diagnostic criteria, 23 of 42 (55%) had a mutation, and seven of nine (78%) 'overlap' patients meeting diagnostic criteria for both CS and BRRS had a mutation. Of the 172 patients with PTEN mutations, 63 (37%) did not meet diagnostic criteria for either CS or BRRS. Compared to the mutation positive patients who met CS/BRRS diagnostic criteria, these patients had similar frequencies of macrocephaly (77%), MR/DD (22.6%), and benign skin lesions (37%), but all other clinical features were seen at half the frequency or less (data not shown).
Observed versus expected cancers
Because the age at diagnosis was not ascertained for the subjects in this study, we were unable to do a typical comparison of observed to expected numbers of cancers compared to the general population. However, as a surrogate we assessed cancer rates at the time of molecular diagnosis for the entire cohort, and separately for female versus male subjects over age 18 years. a) there are six or more facial papules, of which three or more must be trichilemmoma, or b) cutaneous facial papules and oral mucosal papillomatosis, or c) oral mucosal papillomatosis and acral keratoses, or d) palmoplantar keratoses, six or more 2. Two or more major criteria, but one must include macrocephaly or LDD; or 3. One major and three minor criteria; or 4. Four minor criteria
Because of the relatively small number of cancers, analysis was only possible by grouping thyroid, breast, and endometrial cancers together. Given the ages for mutation carriers in this cohort at the time of PTEN testing, the expected combined number of invasive thyroid, breast, and endometrial cancer cases in the general population would be 2.2. We observed 54 cases, giving a ratio of observed to expected cases of 24.5. This difference was statistically significant (p<0.001).
Logistic regression analyses Table 4 shows the results of the logistic regression model for males with macrocephaly. There were a total of 267 males, of which 149 were #18 years of age with macrocephaly. Of these, 44 (29.5%) were found to have a mutation. Lipomas, papillomatous papules, and penile freckling were found to be significant predictors of the presence of a mutation for this gender/age group. The probability of having a mutation for a macrocephalic male #18 years of age with all of these features would be 99.1%. There were only 59 males >18 years of age with macrocephaly in our cohort, of which 31 were found to have a mutation (52.5%). The presence of benign thyroid disease and benign GI lesions were found to be significant in the predictive model. If a male with macrocephaly >18 years of age presented with these two characteristics his probability of having a mutation was 93.3%. Table 5 shows the logistic regression results for females, which were not restricted to subjects with macrocephaly. There were 105 females #18 years of age in this group, of which 21 (20.0%) had a mutation. The analysis showed that benign skin disease and macrocephaly were significant predictors of the presence of a mutation for females #18 years of age. However, the probability of having a mutation for a female #18 years old with these features would only be 44.3%. For females >18 years, macrocephaly, endometrial cancer, trichilemommas, papillomatous papules, benign thyroid disease, and benign GI lesions were all found to be significant predictors of having a mutation. If a female >18 years presented with all of these features, the probability of a mutation was 99.7%. The data obtained from these analyses were used to develop a model which predicts the likelihood of finding a mutation in a patient with various combinations of these clinical features. The model is available online at http://internalmedicine.osu.edu/genetics/research/ tools-for-providers/.
DISCUSSION
CS and BRRS are complex disorders with multiple component features, many of which are common by themselves in the general population. Because of the rarity of these syndromes, the existing literature on the component clinical features of CS/BRRS has been based on compilations of case reports (with their inherent selection biases) and studies of relatively small numbers of patients and families. More importantly, the majority of these reports predate the adoption of the CS Consortium diagnostic criteria in 1996. The current diagnostic criteria used for CS are based on these reported features, and are thus sensitive to their accuracy. As the primary laboratory in the USA offering clinical testing for PTEN gene mutations during the study period, we were in a unique position to assemble the world's largest reported series of clinically tested, mutation positive patients on which to assess the clinical features and performance of the Consortium diagnostic criteria.
Benign clinical features
The frequencies of a number of benign clinical features differed significantly for our cohort, compared to the literature. Consistent with more recent reports, 9 29 30 the frequency of macrocephaly among mutation positive patients (84%) was much higher than prior estimates. 15 This most likely reflects the fact that head circumferences have been more routinely obtained on CS patients since the adoption of the Consortium criteria.
Adult females had frequencies of benign breast disease (46%) and uterine fibroids (26%) that were significantly lower than the reported rates for CS patients, and not above the background rates of 60% and 70e80%, respectively, reported for the general US population. 31e33 This raises into question the usefulness of these features as part of the diagnostic criteria, and indeed neither was found to be a significant predictor of a mutation in our modelling.
The rate of benign skin lesions among all patients (77%) was also significantly lower than commonly reported. Based on early reports in the dermatology literature, papillomatous papules, trichilemmomas, acral keratoses, and mucosal lesions were thought to affect nearly all patients with CS. 34 35 While it is possible that CS related skin lesions may have been underreported in our cohort, it is also likely that prior reports overestimated the frequency of skin lesions with CS. Regardless, our findings suggest that readily apparent skin manifestations may be less common among patients with PTEN mutations than previously reported, and that a formal dermatological examination may be helpful in the diagnostic workup of suspected patients.
Malignant features
The high frequencies of breast, endometrial, and thyroid cancers in our cohort were expected. Given the overall young age of our cohort, and that additional cancers might be diagnosed at later ages, our study may well underestimate the lifetime cancer risks. Among adult women with mutations in our cohort, 28/69 (41%) had a diagnosis of invasive breast cancer at the time of testing, with a mean age at molecular testing of 47.6 years (range 33e64 years). No males with breast cancer were identified, consistent with the literature in which only two cases have been reported. 7 36 An association between PTEN mutations and risk for male breast cancer is therefore not supported by our data, although it cannot be ruled out.
Endometrial cancer was seen in 12/69 (17%) adult women, which is significantly higher than previous estimates. Six of these women had also had breast cancer, but it is unknown whether their breast cancers predated their endometrial cancer diagnoses, nor whether they had been treated with tamoxifen, which would have increased their endometrial cancer risk. Thyroid cancer was seen in 13 patients (7.6% overall). Interestingly, it was seen at similar rates among adult women (13%) and men (11%), in contrast to the approximately 3 to 4:1 female to male ratio seen in the general population. Given the young mean age of our cohort there was also a suggestion in our data of increased rates of GI cancers, and renal cell carcinoma. A recent report summarising cancers identified in CS cases reported in the medical literature found cumulative risks of cancer to age 70 of 81% for breast cancer, 21% for thyroid cancer, 19% for renal cancer, and 16% for colon cancer. 37 However, the diagnostic criteria used were slightly different from Consortium criteria and only 46% of their cases had a documented PTEN mutation. Another recent report of patients with PTEN mutations found colorectal cancer in 7.1% of patients overall, and in 13% of those who had had endoscopies. 23 A number of other clinical features have been suggested to be increased among patients with PTEN mutations, but were not supported by our data. Specifically, none of the 172 patients had reported brain cancers and only one had a reported genitourinary malformation. While melanoma has been suggested to be increased in CS, it was reported in only 2/172 mutation positive cases in our study. These were in women ages 45 and 49 years at testing, but we do not know their ages of diagnosis. SEER data estimate the probability of a woman developing melanoma by age 50 as approximately 0.4%. 18 
CS Consortium diagnostic criteria
Our data also suggests that the specificity of the Consortium criteria are lower than previously estimated. Only 79 of 230 subjects (34%) meeting CS diagnostic criteria in our cohort had a detectable mutation, which is significantly lower than the 80% previously reported. 7 This suggests that the Consortium diagnostic criteria are not as robust at identifying patients with germline PTEN mutations as previously thought. In comparison, 23 of 42 (55%) BRRS patients had a detectable mutation, which is consistent with the literature. 13 Specific components of the Consortium criteria are also called into question. For example, looking only at the simplest pairings of two major features, the mutation detection rates in our study were generally low: macrocephaly/breast cancerd23/64 (36%); macrocephaly/thyroid cancerd10/25 (40%); macrocephaly/ endometrial cancerd8/10 (80%); breast/thyroid cancersd1/56 (1.8%); breast/endometrial cancers 6/17 (35%); and thyroid/ endometrial cancersd3/7 (43%). Yet these are almost certainly overestimates for individuals presenting with only two major features since the majority of patients in our cohort had several other features in addition to the pairs indicated. This was most apparent for the macrocephaly/endometrial cancer category, where eight of 10 women were found to have a mutation: of the eight, five also had a primary breast cancer and a sixth patient had a primary thyroid cancer. These patients also had numerous minor clinical features as well. A recent publication on a small cohort of women with breast cancer also found that macrocephaly was not a significant differentiator between women with or without mutations, and that only 17% of women meeting CS Consortium diagnostic criteria were found to have a mutation. 38 This raises questions as to the validity of the 'two major features' diagnostic criterion. The low rate of mutation detection in this study may be partially attributed to inaccurate diagnoses or incomplete ascertainment of clinical features by the heterogeneous group of clinicians who referred patients for testing. This is in contrast to some prior research studies in which the diagnoses were made by a single research team. 7 13 However, we believe that the conditions leading to referral for clinical testing in this study represent more 'real world' conditions under which CS/BRRS clinical features are ascertained and testing is ordered. In addition, the vast majority of tests (approximately 90%) were ordered by genetics or cancer genetic programmes, regardless of whether or not a mutation was found in the patient. These centres would be expected to be the most experienced at identifying patients meeting CS criteria. This would argue for modification of the CS diagnostic criteria to focus on clinical features more strongly indicative of the presence of a PTEN mutation, and less on features such as benign breast disease and uterine fibroids, which are common in the general population and were not seen at increased rates in our cohort.
Limitations
This study has a number of limitations. Most significantly, there is an inherent referral bias present because those patients with more clinical features of CS/BRRS are obviously more likely to get tested. In addition, the vast majority of subjects (142) were the first identified affected member in their family and thus were more likely to have significant clinical features. However, since only 30 subjects were tested because of having an affected relative, we were not able to exclude the probands from our analyses. Because we found no significant differences in the frequencies of the clinical features between probands and tested relatives (data not shown), these groups were combined in our analyses. Our data thus may overestimate the frequency of PTEN related clinical features. A less biased assessment would come from studying family members only and excluding the proband. However, given the rarity of this disease, this will be very difficult to do. As the only clinical laboratory in the USA testing for PTEN mutations during much of our 8 year accrual period, we were still able to collect only 30 relatives with mutations. Statistically significant conclusions cannot be made on such a small cohort. We thus felt it was important and clinically informative to provide the data we had available on the large cohort of mutation positive probands.
As noted above, the patients in our study were not directly evaluated by our team and the accuracy of the clinical histories reported by the referring clinicians may vary widely. While this was guided by the required use of a clinical features checklist, it is possible that incomplete and/or inaccurate histories may have been reported. However, incomplete histories would lead to an underestimate of the frequencies of clinical features.
A final limitation was that only sequencing was used for analysis of the PTEN gene, and thus some mutations may have been missed. However, the existing literature suggests that these are likely to be few. One group found variations in the PTEN promoter in approximately 2% of patients meeting CS diagnostic criteria. 11 The same group found large rearrangements or deletions in 0 of 95 CS patients and three of 27 BRRS patients who had no detectable mutation on DGGE analysis. More recently, deletions were found in three of 15 CS patients who were negative for PTEN mutations on DGGE analysis. 10 Assuming that DGGE detects mutations in 40e80% of patients meeting CS diagnostic criteria (based on the literature and the current study), this extrapolates to deletions being detected in 4e12% of patients with CS.
Conclusions
In conclusion, our findings support the previously reported increased frequencies of breast, endometrial, and thyroid cancers and many but not all of the component non-malignant features in patients with PTEN mutations. Our data also suggest that endometrial cancer may be more frequent than previously reported, and that kidney and colon cancer may also be increased in frequency. Further work is needed to confirm these possible associations.
We also found evidence that the Consortium diagnostic criteria for CS are significantly less specific than previously estimated. In particular, most of the pairings of macrocephaly and one other major criteria, which meet current CS diagnostic criteria, led to low mutation detection rates. An association between PTEN mutations and certain minor diagnostic criteria, such as benign breast disease and uterine fibroids, was not found in our cohort. This work suggests that the Consortium diagnostic criteria should be revised to put greater emphasis on the most predictive clinical features. Based on our data, we have developed a model (http://internalmedicine.osu.edu/genetics/ research/tools-for-providers/) which can be used to predict the likelihood of a PTEN mutation for a patient based on their constellation of clinical features. We hope that it can provide guidance in clinical practice in identifying patients appropriate for PTEN testing.
